The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus

Treatments in Endocrinology

Volumn 1, Issue 1, 2002, Pages 13-20

  Mooradian, Arshag D ^a   Chehade, Joe ^a   Thurman, Jerome E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NG 2100; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EDEMA; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIVER FAILURE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; WATER RETENTION; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 0003072205     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201010-00002     Document Type: Review

References (71)

1. American Diabetes Association. Diabetes 1996 Vital Statistics. Alexandria (VA): American Diabetes Association, 1996
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998; 21: 1414-31
3. Beckles GLA, Engelgau MM, Narayan KMV, et al. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 1998; 21: 1432-8
4. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care 2001; 24 Suppl. 1: S1-133
5. American Diabetes Association. Complete guide to diabetes. Alexandria (VA): American Diabetes Association, 1997
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
8. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
9. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study: questions answered and issues remaining. Drugs Aging 2000; 16: 159-64
10. Turner RC, Call CA, Frighi V, et al. The UKPDS Group: glycemic control with diet, sulfonylurea, metformin, or insulin in patients with multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12
11. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 Suppl.: S21-5
12. Anonymous. Consensus Development Conference on Insulin Resistance. Nov 5,6, 1997. American Diabetes Association. Diabetes Care, 1998; 21: 310-4
13. Haffner SM, D'Agostino Jr R, Mykkanen L. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-8
14. Turner NC, Clapham JC. Insulin resistance, impaired glucose tolerance and noninsulin-dependent diabetes, pathologic mechanism and treatment: current status and therapeutic possibilities. Prog Drug Res 1998; 51: 33-94
15. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988 Jun; 37 (6): 667-87
16. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia. Drugs 1999; 57: 19-29
17. Robertson R, Porte Jr D. The glucose receptor: a detective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 1973; 52: 870-6
18. DeFronzo RZ, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15 (3): 318-68
19. Gerich J. Address the insulin secretion defect: a logical first-line approach. Metabolism 2000; 49 Suppl. 2: 12-6
20. Bak H, Moller N, Schmitz O, et al. In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: Effects of diet treatment. Diabetologia 1992; 35: 777-84
21. Beck-Nielsen H, Pedersen O, Lindskov H. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979; 90: 103-12
22. Freidenberg G, Reichart D, Olefsky J, et al. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus: effect of weight loss. J Clin Invest 1988; 82: 1398-406
23. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94
24. Boyko EJ, Fujimoto WY, Leonetti DL, et al. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23: 465-71
25. Campbell S, Mooradian AD. Diabetes mellitus. In: Bressler R, Katz MD, editors. Geriatric pharmacy. New York: McGraw Hill, Inc., 1993: 409-25
26. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000; 60: 95-113
27. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26: 539-51
28. Bailey CJ, Turner RC. Metformin. New Engl J Med 1996; 334: 574-9
29. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9
30. Steppan CM, Baily ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 292-3
31. Burant CF, Sreenan S, Hirano KI, et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest 1997; 100: 2900-8
32. Steppan CM, Brown EJ, Wright CM, et al. A family oftissue-specific resistin like molecules. Proc. Nat'l. Acad. Sci. (USA) 2001; 98: 502-6
33. Willson TM, Brown PJ, Sternbach DD, et al. The PPARS: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50
34. Thampy GK, Haas MJ, Mooradian AD. Troglitazone stimulates acetyl-CoA carboxylase activity through a posttranslational mechanism. Life Sci. 2000, in press
35. Wang M, Wise SC, Leff T, et al. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator activated receptor γ. Diabetes 1999; 48: 254-60
36. Fukui Y, Masui S, Osada S, et al. A new thiazolidinedione, NG-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and increases uncoupling protein I in white adipose tissue of KKAY obese mice. Diabetes 2000; 49: 759-67
37. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes 1997; 46: 701-10
38. Cavaghan MK, Ehrmann DA, Byrne MM, et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-7
39. Sreenan S, Keck S, Fuller T, et al. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 1999; 276: E1119-29
40. Finegood DT, McArthur MD, Kojwang D, et al. Beta cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-9
41. Diabetes Prevention Program NIH. NIDDK home page. Press release. Available from URL: http:\www.niddk.nih.gov [Accessed 2001 Aug 21]
42. Sak Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and -cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990; 127: 1580-9
43. Martin G, Schoonjans K, Shaels B, et al. PPAR γ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137: 575-80
44. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-31
45. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect ofpioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-6
46. Minamikawa J, Tanabe S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-20
47. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-35
48. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertension 1995; 8: 3160-320
49. Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997; 272: E989-96
50. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-9
51. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR gamma in endothelial function. Biochem Biophys Res Commun 1999; 258: 431-5
52. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539-47
53. Walker AB, Naderali EK, Chattington PD, et al. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47: 810-4
54. Ishizuka T, Itaya S, Wada H, et al. Differential effect of antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47: 1494-500
55. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-11
56. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000; 283: 1695-702
57. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-84
58. Phillips LS, Grunberger G, Miller E, et al. For the Rosiglitazone Clinical Trials Study Group. Once- and twice- daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15
59. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8
60. Scherbaum W, Goke B. For the German Pioglitazone Study Group. The effect of pioglitazone vs. acarbose on the lipid profile in patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A454
61. Prince MJ, Zagar AJ, Robertson KE. Effect of pioglitazone on HDL-c, a cardiovascular risk factor in type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A128
62. Davidson PC, Sabbah HT, Steed RD, et al. Pioglitazone versus rosiglsitazone therapy in randomized follow up in patients previously treated with troglitazone [abstract]. Diabetes 2001; 50 Suppl. 2: A109
63. King AB, Armstrong D. Comparison of the glucose and lipid effect of rosiglitazone (Ros) and pioglitazone (Pio) following conversion from troglitazone (Tro) treatment [abstract]. Diabetes 2001; 50 Suppl. 2: A120
64. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones [letter]. Diabetes Care 2000; 23: 557
65. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocrine Pract 2001; 7: 162-9
66. Howard BV, Robbins DC, Sievers ML. et al. LDL Cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000; 20: 830-5
67. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl. A: 5A-10
68. King AB, Armstrong D. Characteristics of the patients who gain weight while on pioglitazone treatment [abstract]. Diabetes 2001; 50 Suppl. 2: A120
69. Rezulin (troglitazone) Package Insert. Ann Arbor (MI): Parke Davis. Jun 1999
70. Al-Salman J, Heider A, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132: 121-4
71. Mooradian AD. Rosiglitazone: a viewpoint. Drugs Aging 1999; 57: 931